Le Lézard
Classified in: Health, Science and technology
Subject: PER

Revian Announces Amy Keish Joins Company as Vice President of Healthcare Sales


MORRISVILLE, N.C., April 4, 2024 /PRNewswire/ -- REVIAN Inc., an aesthetic medical technology company using precise wavelengths of LED light to rejuvenate hair and skin, announced today that Amy Keish will be joining the Company as Vice President of Healthcare Sales. Ms. Keish brings more than 18 years of industry experience in the hair restoration market, most recently serving as the National Director of Senior Counselors for Bosley.

"I am thrilled to join the Revian team and help bring relief for those suffering from Androgenetic Alopecia. The Revian Red system's differentiated attributes make it ideal for not only single mode therapy but also multi modal therapies which position it to continue to take advantage of the significant growth the market is seeing. Revian's unique benefits to women make this a particularly exciting opportunity."

Ms. Keish graduated from Elon University and began her career in hair restoration at The Hair Club, ultimately progressing to Regional Director, before she joined Bosley as the National Director of Senior Counselors. She will work with Tim Waite who is continuing with the company in his sales capacity.

"Amy has already demonstrated a dynamic ability to lead in the complicated hair restoration industry early in her career." said Revian's Chief Executive Officer John Oakley, "Adding her to our team at this point in Revian's life cycle will help fuel our already dynamic growth."

About the Revian Red Hair Growth System
The award winning REVIAN RED System is an FDA cleared, lightweight wireless cap controlled by a mobile App that functions to provide a hair loss treatment for men and women using precision LED light. The device's patented dual wavelength LED technology provides broader scalp coverage and better skin penetration than red lasers traditionally used in low level light therapy (LLLT) producing the best clinical trial performance of any hair rejuvenation treatment available on the market. REVIAN RED uses a patented combination of two wavelengths of LED light to stimulate the production and release of nitric oxide, proven to increase local blood flow, reduce inflammation, and inhibit DHT production which provides the right environment for new hair growth. REVIAN RED's cleared indication for use is the treatment of androgenetic alopecia, to promote hair growth in males who have Norwood-Hamilton classifications of IIa-V patterns of hair loss and to treat androgenetic alopecia and promote hair growth in females who have Ludwig-Savin Scale I-1 to II-4, II1, II2 or frontal patterns of hair loss; both with Fitzpatrick Skin Types I-IV.

About Revian, Inc.
Revian, an operating subsidiary of KNOW Bio, LLC, is an aesthetic medical technology innovator dedicated to stimulating the body's natural processes to rejuvenate hair and skin with light. The company creates products that precisely deliver light and allow people to experience its regenerative potential in the convenience of their own homes. Revian is committed to partnering with health-care providers and other caring professionals to deliver meaningful results, backed by scientific data. For more information, visit www.revian.com.

Contact:
John Oakley
REVIAN, Inc.
[email protected]
919-939-7715

SOURCE REVIAN, Inc.


These press releases may also interest you

at 09:10
Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled "Stimulation of Mesenchymal Stem Cell Therapeutics...

at 09:07
Daniel M. Geynisman, MD, is being announced as the new Editor-in-Chief for JNCCN?Journal of the National Comprehensive Cancer Network. Dr. Geynisman has a long history of working with NCCN in a variety of roles and served as medical oncology section...

at 09:05
Zephyr AI, Inc., a high-growth healthcare technology company committed to developing artificial intelligence (AI) solutions to democratize precision medicine, has announced that veteran biotechnology executive John Applegate has joined the company as...

at 09:05
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced dosing of the first patient in the Phase 1 clinical trial of A2B694. The multi-center...

at 09:05
CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from...

at 09:02
Understood.org, a leading nonprofit empowering more than 70 million neurodivergent people who have learning and thinking differences, such as ADHD and dyslexia, today announced the results of a Harris Poll of over 2,000 U.S. adults ages 18+. The poll...



News published on and distributed by: